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Abstract
Background: In Taiwan, there is a high incidence of breast cancer and a high prevalence of viral hepatitis. In this
case-control study, we used a population-based insurance dataset to evaluate whether breast cancer in women is
associated with chronic viral hepatitis infection.
Methods: From the claims data, we identified 1,958 patients with newly diagnosed breast cancer during the
period 2000-2008. A randomly selected, age-matched cohort of 7,832 subjects without cancer was selected for
comparison. Multivariable logistic regression models were constructed to calculate odds ratios of breast cancer
associated with viral hepatitis after adjustment for age, residential area, occupation, urbanization, and income. The
age-specific (<50 years and ≥50 years) risk of breast cancer was also evaluated.
Results: There were no significant differences in the prevalence of hepatitis C virus (HCV) infection, hepatitis B virus
(HBV), or the prevalence of combined HBC/HBV infection between breast cancer patients and control subjects (p =
0.48). Multivariable logistic regression analysis, however, revealed that age <50 years was associated with a 2-fold
greater risk of developing breast cancer (OR = 2.03, 95% CI = 1.23-3.34).
Conclusions: HCV infection, but not HBV infection, appears to be associated with early onset risk of breast cancer
in areas endemic for HCV and HBV. This finding needs to be replicated in further studies.
Background
Breast cancer is one of the most common cancers and
the leading cause of death in women worldwide [1].
Over the past several decades, the incidence of breast
cancer has increased globally [2,3], with the greatest
increase occurring in Asian countries [2,4,5]. Risk fac-
tors for breast cancer include benign breast disease, fer-
tility, obesity, particularly after menopause, familial and
genetic factors, and oral contraceptive use [6-9]. The
etiology and progression of breast cancer remain incom-
pletely understood; therefore, novel routes of disease
pathogenesis are important to consider.
Richardson proposed that breast cancer risk may be
associated with late exposure to common viruses [10].
Zur Hausen stated that approximately 19% of the glo-
bal cancer burden can be linked to five infectious
agents, namely Epstein-Barr virus (EBV), human Papil-
lomaviruses (HPV), hepatitis B virus (HBV), hepatitis
C virus (HCV), and helicobacter pylori [11]. His find-
ings, therefore, suggest that viruses may be considered
as a potential cause of breast cancer [11-13]. Yasui et
al. provided supporting evidence for the hypothesis
that “delayed” exposure to Epstein-Barr virus is a risk
factor for breast cancer [14]. Mazouni et al. also sug-
gested that Epstein-Barr virus is a marker of biological
aggressiveness in breast cancer [15]. In addition, de
Villiers and his colleagues demonstrated the occur-
rence of HPV in nipple and areolar tissues in patients
with breast carcinoma [12]. Besides the well estab-
lished association with primary liver cancer, HCV
infection has been associated with other neoplasms
including non-Hodgkin lymphoma [16], and smoking
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pancreas, lung and kidney, and the oropharygeal can-
cer [17]. In the same token, HBV infection also has
been associated with pancreas cancer [18], intrahepatic
cholangiocaricinoma and non-Hodgkin lymphoma
[19,20]. Whether there is a potential link between
chronic HCV or HBV infection and the risk of devel-
oping breast cancer has yet to be well investigated.
In Taiwan, the incidence of breast cancer has
increased annually by 8% since 2003 [21]. In addition,
the peak age for breast cancer is between 40 years and
50 years in Taiwan whereas the peak age in Western
countries is between 60 years and 70 years [2]. Taiwan
is a country in which HBV infection is endemic and a
country with a high prevalence of HCV [22]. The fact
that Taiwan is endemic for viral hepatitis and has a high
prevalence of breast cancer provides an excellent setting
in which to study the association of these 2 entities.
Therefore, we used a nationwide population-based data-
set to assess the possible association between chronic
viral hepatitis infection and breast cancer as well as the
possibility that chronic viral hepatitis is a risk factor for
early onset breast tumors in Taiwan.
Materials and methods
Data sources
Data used in this study were retrieved from the National
Health Insurance Research Database (NHIRD), which is
maintained by the National Health Research Institute
(NHRI), Taiwan. The single-payer National Health
Insurance (NHI) program in Taiwan was initiated in
March, 1995 to provide comprehensive and affordable
health care to all of the island’s residents. By the end of
1996, this insurance program covered more than 96% of
the population and has contracted with 97% of hospitals
and clinics in the country [23]. The NHRI randomly
selected data from the insured population to establish a
representative sub-dataset comprised of 1 M insured
enrollees during the period 1996-2000. There is no sig-
nificant difference in the distribution of gender, age, or
average payroll-related insurance payment between the
individuals in the NHRID and the original medical
claims for all enrollees under the NHI program. The
data files are linkable through an encrypted but unique
personal identification number and thus provide
patient-level information on demographic characteris-
tics, medical history, registry of medical facilities, details
of inpatient orders, ambulatory care visits, dental ser-
vices, and prescriptions. Diagnoses are coded according
to the International Classification of Disease, Ninth revi-
sion (ICD-9-CM). As the dataset was released with de-
identified secondary data for public research purposes,
the study was exempt from full review by the Institu-
tional Review Board.
Study sample
Patients with newly diagnosed breast cancer (ICD-9-CM
code 174 and 175) during the period 2000-2008 were
identified from the registry for Catastrophic Illness
Patients Database. The insur a n c ec o v e r a g ef o rc a t a -
strophic illnesses is the extension of the Taiwan’sN H I
to protect people with serious disease against cata-
strophic financial burden and subsequent impoverish-
ment. Breast cancer was placed in the category of NHI-
defined “Catastrophic Illnesses”, and the NHI covers the
treatment costs incurred by this disease. In this study,
our purpose was to observe mainly the association
between chronic viral hepatitis (HBV or HCV) and
breast cancer. The etiologies of other types chronic
hepatitis, such as autoimmune, chemical, alcoholic-
related hepatitis, as well as non-alcoholic fatty liver dis-
ease were not included as our study subjects. For HBV
infection recorded in the database, the presence of HBs
Ag was the major serum marker. Patients with the his-
tory of HIV were excluded from the present study to
minimize the inclusion of occult HBV infection (the
persistence of hepatitis B virus (HBV) in hepatitis B sur-
face antigen (HBs Ag) negative) among patients with the
HBV/HIV coinfection [24]. Hence, we excluded patients
with a history of HIV (ICD-9-CM 042, 043, 044, and
V08), chronic hepatitis (ICD-9-CM 070.9, 571.4, 571.8,
571.9, and 573.3) without mentioning hepatitis B (ICD-
9-CM 070.2, 070.3, and V02.61) or hepatitis C (ICD-9-
CM 070.41, 070.44, 070.51, 070.54, and V02.62) infec-
tion. After excluding two cases of HIV and 468 subjects
with chronic hepatitis without mentioning hepatitis B or
hepatitis C, 1958 subjects with breast cancer were
enrolled in this study.
Control subjects were randomly extracted from the
remaining subjects in the database with an identical
exclusion criterion to cases. The comparison group
comprised randomly selected age- and sex-matched
individuals without a history of breast cancer. The con-
trol to patient ratio was 4:1. The age of each study sub-
ject was based on the difference in time between the
index date and the date of birth. Originally, 434,659
female subjects were retrieved from the NHIRD. After
excluding 9,738 subjects with cancers other than breast
cancer, 260 cases with HIV, and 69,756 subjects with
chronic hepatitis other than hepatitis B or hepatitis C,
354,905 subjects were eligible for the selection of con-
trol subjects. Finally, a total of 7,832 controls were
enrolled in this study.
Statistical analysis
We compared the distributions of demographic charac-
teristics, including age, occupation, urbanization level,
and personal income between breast cancer patients and
control subjects using Chi-square tests. Potential
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income, level of urbanization (4 levels with Level 1
referring to the “most urbanized” and Level 4 referring
to the “least urbanized” communities), and the geogra-
phical location of the community in which the patient
resided (northern, central, eastern, and southern Tai-
wan). We selected NT $15,000 and NT $30,000 as the
income level cutoff points in Taiwan. Multivariable
logistic regression analysis was conducted to assess the
association of viral hepatitis with the risk of breast can-
cer, after adjusting for variables that were significantly
related to breast cancer from the prior Chi-square ana-
lyses. The age-specific odds ratios of breast cancer asso-
ciated with viral hepatitis were also examined by two
individual logistic regression models (one for age <50
years and the other one for age ≥50 years). To address
the hypothesis of the presence of an association between
HCV and early onset breast cancer, interaction between
HCV status and age of developing breast cancer was
tested by a logistic regression analysis. All analyses were
performed by SAS statistical software (version 9.1 for
Windows; SAS Institute, Inc., Cary, NC, USA), and the
significance level was set at 0.05.
Results
Characteristics of the study subjects
Table 1 compares the distributions of demographic
characteristics between the patient group and the con-
trol group. Most subjects were in the 40-60-year age
group (64.3% in the patient group and the control
group). Breast cancer patients were more likely than
control subjects to have white-collar occupations (55.4%
vs. 51.3%, p = 0.001), live in areas with the highest urba-
nization level (34.4% vs. 31.7%, p =0 . 0 3 ) ,a n dh a v e
higher incomes (15.7% vs. 12.6%, p = 0.0004).
Table 2 shows the prevalence of viral hepatitis B and
C in the study subjects. Although the patient group
tended to have higher proportions of HCV (2.9%
Table 1 Demographic characteristics between breast cancer patients and non-breast cancer subjects in 2000-2008
Variables Total N = 9790 Breast cancer p-value*
No N = 7832 Yes N = 1958
n (%) n (%) n (%)
Age, years 1.00
20-29 145 (1.5) 116 (1.5) 29 (1.5)
30-39 1305 (13.3) 1044 (13.3) 261 (13.3)
40-49 3630 (37.1) 2904 (37.1) 726 (37.1)
50-59 2665 (27.2) 2132 (27.2) 533 (27.2)
60-69 1205 (12.3) 964 (12.3) 241 (12.3)
≥ 70 840 (8.6) 672 (8.6) 168 (8.6)
Occupation 0.001
White collar 5098 (52.1) 4014 (51.3) 1084 (55.4)
Blue collar 3538 (36.1) 2898 (37.0) 640 (32.7)
Others 1154 (11.8) 920 (11.8) 234 (12.0)
Urbanization level 0.03
1 3154 (32.2) 2480 (31.7) 674 (34.4)
2 2928 (29.9) 2335 (29.8) 593 (30.3)
3 1675 (17.1) 1351 (17.3) 324 (16.6)
4 2032 (20.8) 1666 (21.3) 366 (18.7)
Region 0.24
North 4762 (48.7) 3782 (48.3) 980 (50.1)
Central 1880 (19.2) 1495 (19.1) 385 (19.7)
South 2330 (23.8) 1888 (24.1) 442 (22.6)
East and Islands 817 (8.4) 667 (8.5) 150 (7.7)
Income 0.0004
< 15,000 3116 (31.8) 2481 (31.7) 635 (32.4)
15,000-29,999 5381 (55.0) 4365 (55.7) 1016 (51.9)
≥ 30,000 1293 (13.2) 986 (12.6) 307 (15.7)
Urbanization level: 1 Indicate the highest level of urbanization and 4 the lowest
*Chi-square test
Su et al. BMC Cancer 2011, 11:495
http://www.biomedcentral.com/1471-2407/11/495
Page 3 of 7vs.2.3%), HBV (6.3% vs.6.1%) or both (1.0% vs.0.9%),
there were no significant differences in the prevalence of
those infections between patients and controls (p =
0.48).
Overall risk and age-specific risk of breast cancer
The logistic regression analysis showed that viral hepati-
tis was not significantly associated with breast cancer,
although the risk was greater for subjects with HCV
(adjusted OR = 1.28, 95% CI = 0.95-1.78) than for those
with HBV (adjusted OR = 1.05, 95% CI = 0.85-1.28) or
both (adjusted OR = 1.08, 95% CI = 0.65-1.80) (Table
2).
However, the multivariable regression model revealed
that HCV patients aged less than 50 years had a signifi-
cant 2.03-fold higher risk of breast cancer (OR = 2.03,
95% CI = 1.23-3.34) (Table 3). The interaction between
HCV status and age (<50 years and ≥50 years) of devel-
oping breast cancer was statistically significant (p =
0.019) (not shown in Table).
Discussion
In this large-scale, population-based study in an area
where both viral hepatitis and breast cancer are preva-
lent, we found no significant association between breast
cancer risk and HBV or HCV seropositivity; however,
age-stratification analysis showed that HCV patients
aged less than 50 years had a significant two-fold greater
risk of breast cancer.
Although breast cancer is mainly a postmenopausal
disease, breast cancer in younger females often shows
more aggressive clinical features and worse prognosis
[3]. Studies have shown that high-risk and low-risk
tumors present different age distributions, suggesting
that breast cancer comprises a mixture of two different
disease processes [3,25]. The epidemiology of breast
cancer in women living in Asia differs from that in
women living in North America or Europe. The peak
incidence age is between 40 years and 50 years among
Asian women, whereas in the United States and Europe,
it peaks among women in the sixth decade of life
[2,5,26,27]. This variation in peak incidence age may be
due to multiple factors, including geographic variation,
racial/ethnic background, genetic variation, lifestyle,
environmental factors, socioeconomic status, utilization
of screening mammography, stage of disease at diagno-
sis, and the availability of appropriate care [1,21]
In 1997, Richardson proposed that breast cancer risk
is associated with late exposure to common viruses [10].
Since then, numerous studies have shown that EBV,
HPV, and cytomegalovirus infections are associated with
the development of breast cancer [12,14,15,28,29].
Few studies, however, have evaluated the relationship
between HCV or HBV infection and breast tumor
development. A higher prevalence of HCV has been
observed in elderly patients with tumors of the colon/
rectum, prostate, breast, bladder, or kidney [30-32] as
well as in elderly patients with hepatocarcinoma [33]
or non-Hodgkin lymphoma [16,19]. Malaguarnera et
al. reported that HCV RNA was detectable in sera in
11% of breast cancer patients and in 6.6% of control
subjects, although there was no significant difference
Table 2 Comparison of hepatitis prevalence between breast cancer patients and non-breast cancer subjects in 2000-
2008
Viral hepatitis B & C Total N = 9790 Breast cancer
No N = 7832 Yes N = 1958
n (%) n (%) n (%) OR
a (95% CI)
No 8862 (90.5) 7102 (90.7) 1760 (89.9) 1.00 (reference)
HCV 234 (2.4) 178 (2.3) 56 (2.9) 1.28 (0.95-1.75)
HBV 603 (6.2) 480 (6.1) 123 (6.3) 1.05 (0.85-1.28)
HBV + HCV 91 (0.9) 72 (0.9) 19 (1.0) 1.08 (0.65-1.80)
aAdjusted for area, occupation, urbanization, and income
Table 3 Odds ratios and 95% confidence interval of breast cancer associated with viral hepatitis by age
Viral hepatitis B & C Age < 50 years Age ≥ 50 years
Cases Controls OR
a (95% CI) Cases Controls OR
a (95% CI)
No 910 3722 1.00 (reference) 850 3380 1.00 (reference)
HCV 24 48 2.03 (1.23-3.34)* 32 130 1.00 (0.67-1.49)
HBV 72 267 1.10 (0.84-1.45) 51 213 0.97 (0.71-1.33)
HBV + HCV 10 27 1.59 (0.77-3.31) 9 45 0.83 (0.40-1.71)
aAdjusted for area, occupation, urbanization, and income
*p < 0.01 based on Wald tests
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reported that HCV infection most likely plays an
important role in the development of hepatocellular
carcinoma as well as breast cancer [32]. In contrast,
the results of a recent case-control study conducted by
Larrey and his colleagues suggest that chronic HCV
infection is not a strong promoter of breast carcinoma
in adult females of any age [31]. However, a relatively
small number of breast cancer patients in the control
group may have masked the true significance of the
infection after age stratification. Similarly, we found
that chronic HCV infection was not significantly asso-
ciated with breast cancer; however, after stratification
by age (sub-grouped into <50 years and ≥50 years),
chronic HCV infection was more prevalent among
patients with early-onset breast cancer than among
those with late-onset of the disease. This finding also
suggests that breast cancer may comprise a mixture of
two different disease processes, and that HCV may act
as a promoter of carcinogenesis in young patients.
Further studies are needed.
The mechanism responsible for the oncogenetic role
of HCV is not well understood, but it involves immunity
and autoimmunity disorders [30,34,35]. Mechanisms of
direct and indirect carcinogenesis by which infections
may contribute to cancer development have been sug-
gested. Immunosuppression or induction of reactive
oxygen species via inflammatory reactions have been
suggested as the two most prominent pathways for
indirect infectious carcinogens. Unlike the immunosup-
pressive mechanism induced by HIV, the mechanism by
which Hepatitis B and C viruses contribute to cancer
still remains obscure [11].
In this study, neither infection with HBV alone nor
HBV/HCV coinfection was correlated with breast can-
cer. HBV and HCV are both hepatotropic viruses.
Their coinfection is associated with clinically and his-
tologically more severe liver disease and higher risk of
the development of hepatocellular carcinoma [22,36].
However, HCV infection has been reported to predis-
pose patients to extrahepatic disorders involving renal,
dermatologic, hematologic, and rheumatologic systems
as well as autoimmune abnormalities [37-39]. Extrahe-
patic manifestations may result from immunologic
t r i g g e r e dm e c h a n i s m sa sw e l la sv i r u si n v a s i o na n d
replication that affect extrahepatic tissues and organs.
Only HCV has the lymphotropic character that is
assumed to be the cause of HCV-associated extrahepa-
tic manifestation [40]. That may explain why we found
that HCV, but not HBV, was associated with breast
cancer. Further prospective cohort studies are required
to verify this result.
This study has several important limitations. First,
some hepatitis infected patients without obvious clinical
symptoms might not receive medical services. As a
result, some hepatitis infected subjects are included in
the control group. However, if viral hepatitis infection is
associated causally with breast cancer, this misclassifica-
tion may lead the estimated HRs toward the null and
further strengthen our finding. Therefore, we are confi-
dent of the positive association between HCV and early-
onset breast cancer. Second, using ICD codes to select
patients with diagnoses of breast cancer, HBV infection,
HCV infection, or other comorbid medical conditions
may be less accurate than selecting patients in a clinical
setting. However, the BNHI randomly samples a fixed
percentage of claims from every hospital and randomly
interviews patients and reviews charts each year to verify
the validity of diagnoses and the quality of care. Patients
with confirmed breast cancer in Taiwan are placed in
the category of “Catastrophic Illness”,a n dt h eB N H I
covers the treatment costs incurred by those patients.
Hence, the diagnosis is relatively accurate and the
patients are representative of the population in Taiwan.
Third, the majority of the residents in Taiwan are of
Chinese ethnicity. The ability to generalize the results to
other racial/ethnic groups is unclear given that the
transmission route of viral hepatitis infection in Chinese
might not be completely the same as that in other eth-
nic groups. Finally, important variables that might be
related to both hepatitis and breast cancer were unavail-
able in the insurance claims database, including family
cancer history, body mass index, environmental expo-
sure, nutritional status, physical activity level, hormone
receptor status of breast cancer, cigarette smoking, and
alcohol consumption. Therefore, we cannot rule out
some of the potential confounding effects associated
with these factors.
Conclusions
In summary, this population-based study suggests that
chronic HCV infection is associated with early-onset
breast cancer and that chronic HBV infection is not
associated with breast cancer. Further studies are needed
to apply our finding to other regions or races and to
clarify the underlying pathophysiological mechanisms
behind the association of chronic viral hepatitis with
breast cancer.
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